Document Detail

Infliximab for hidradenitis suppurativa.
MedLine Citation:
PMID:  14632813     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic disease characterized by significant morbidity. Current medical therapies are only minimally effective at treating the disease. Infliximab is a chimeric monoclonal antibody with high affinity for tumour necrosis factor (TNF)-alpha. TNF-alpha is known to induce proinflammatory cytokines and may play an important role in the therapy of a number of disparate inflammatory disorders. Infliximab has shown promise for the therapy of rheumatoid arthritis and psoriasis. OBJECTIVES: Retrospectively to evaluate the effectiveness of infliximab for the treatment of HS. METHODS: A retrospective chart review was performed for patients who received infliximab at the University of Miami Department of Dermatology. Patients were contacted and asked retrospectively to rate their disease activity immediately prior to and after therapy. RESULTS: Patients' self-reported disease activity scores were significantly decreased (P = 0.0001, paired t-test) following infliximab infusion. This correlated with physician-observed clinical improvement. CONCLUSIONS: Infliximab is a promising agent for the treatment of HS. These initial results suggest that infliximab is associated with objective and subjective improvement in HS. Further controlled studies of the efficacy of infliximab and its effect on the course of the disease are warranted.
T P Sullivan; E Welsh; F A Kerdel; A E Burdick; R S Kirsner
Related Documents :
25283053 - Integrative transcriptomic and metabonomic molecular profiling of colonic mucosal biops...
19564713 - biologics in current therapy for inflammatory bowel disease
3890813 - Neurosyphilis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The British journal of dermatology     Volume:  149     ISSN:  0007-0963     ISO Abbreviation:  Br. J. Dermatol.     Publication Date:  2003 Nov 
Date Detail:
Created Date:  2003-11-24     Completed Date:  2004-03-18     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0004041     Medline TA:  Br J Dermatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1046-9     Citation Subset:  IM    
Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine/Cedars Medical Center, 1400 NW 12th Ave. 6 South Dermatology, Miami, FL 33136, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Dermatologic Agents / therapeutic use*
Hidradenitis Suppurativa / drug therapy*
Middle Aged
Patient Satisfaction
Retrospective Studies
Severity of Illness Index
Treatment Outcome
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Dermatologic Agents; 0/infliximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis.
Next Document:  Cross-linked envelopes in nail plate in lamellar ichthyosis.